A common point of opposition to offering buprenorphine in correctional settings is the perceived risk of diversion, disciplinary issues, or safety concerns created by allowing access to buprenorphine.
Vital Strategies supported technical assistance to six county jails in Pennsylvania that had been funded by the Commonwealth to expand access to buprenorphine to incarcerated persons.
This snapshot looks at the reported incidence of diversion, assault, and conduct citations at the six jails in Pennsylvania that together provided buprenorphine to more than 1,000 individuals over an 18 month period through this state-funded grant program.
Recent Abstracts
Information About New Federal Regulations for Opioid Treatment Programs (OTPs)
Centering Country Ownership and Leadership: The Data for Health Initiative’s Approach
Mass Media Campaigns
Data for Health: Advancing Gender Equity
The Index of Tobacco Control Sustainability
Index of Tobacco Control Sustainability (ITCS): India Subnational Tobacco Control
Index of Tobacco Control Sustainability (ITCS): Indonesia Subnational Tobacco Control
Considerations for Planning Childhood Blood Lead Surveillance
Air Quality Monitoring Toolkit: Assessing Second-Hand Smoke in Hospitality Venues
Association between high-threshold practices and buprenorphine treatment termination